1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
2.3. Company Description and Canine Arthritis Treatment Market Research Coverage
3. Canine Arthritis Treatment Market Opportunity Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
4. Market Background
4.1. Technology Evolution
4.2. List of Growth Hacking Manufacturers
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Trends
4.4. Regulatory Scenario
5. Global Economic Outlook
5.1. Canine Arthritis Treatment Market Outlook
6. Key Inclusions
6.1. Canine Arthritis Treatment Market Analysis
6.2. Canine Osteoarthritis Treatment Scenario
7. North America Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028
7.1. Introduction
7.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017
7.2.1. U.S.
7.2.2. Canada
7.3. Market Size (US$ Mn) Forecast By Country, 2018-2028
7.4. Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013-2017
7.4.1. Non-steroidal anti-inflammatory medications (NSAIDs)
7.4.2. Opioids
7.4.3. Stem Cell Therapy
7.4.3.1. Allogeneic Stem Cell
7.4.3.2. Autologous Stem Cell
7.5. Market Size (US$ Mn) Forecast By Treatment Type, 2018-2028
7.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017
7.6.1. Oral
7.6.2. Injectable
7.7. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028
7.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017
7.8.1. Veterinary Hospitals & Clinics
7.8.2. Retail Pharmacies
7.8.3. Drug Stores
7.8.4. E-commerce
7.9. Market Size (US$ Mn) Forecast By End User, 2018-2028
7.10.Market Attractiveness Analysis
7.10.1. By Country
7.10.2. By Treatment Type
7.10.3. By Route of Administration
7.10.4. By End User
7.11.Drivers and Restraints: Impact Analysis
7.12.Key Market Participants – Intensity Mapping
8. Latin America Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028
8.1. Introduction
8.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Market Size (US$ Mn) Forecast By Country, 2018-2028
8.4. Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013-2017
8.4.1. Non-steroidal anti-inflammatory medications (NSAIDs)
8.4.2. Opioids
8.4.3. Stem Cell Therapy
8.4.3.1. Allogeneic Stem Cell
8.4.3.2. Autologous Stem Cell
8.5. Market Size (US$ Mn) Forecast By Treatment Type, 2018-2028
8.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017
8.6.1. Oral
8.6.2. Injectable
8.7. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028
8.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017
8.8.1. Veterinary Hospitals & Clinics
8.8.2. Retail Pharmacies
8.8.3. Drug Stores
8.8.4. E-commerce
8.9. Market Size (US$ Mn) Forecast By End User, 2018-2028
8.10.Market Attractiveness Analysis
8.10.1. By Country
8.10.2. By Treatment Type
8.10.3. By Route of Administration
8.10.4. By End User
8.11.Drivers and Restraints: Impact Analysis
8.12. Key Market Participants – Intensity Mapping
9. Europe Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017
9.2.1. Germany
9.2.2. U.K
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Western Europe
9.3. Market Size (US$ Mn) Forecast By Country, 2018-2028
9.4. Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013-2017
9.4.1. Non-steroidal anti-inflammatory medications (NSAIDs)
9.4.2. Opioids
9.4.3. Stem Cell Therapy
9.4.3.1. Allogeneic Stem Cell
9.4.3.2. Autologous Stem Cell
9.5. Market Size (US$ Mn) Forecast By Treatment Type, 2018-2028
9.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017
9.6.1. Oral
9.6.2. Injectable
9.7. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028
9.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017
9.8.1. Veterinary Hospitals & Clinics
9.8.2. Retail Pharmacies
9.8.3. Drug Stores
9.8.4. E-commerce
9.9. Market Size (US$ Mn) Forecast By End User, 2018-2028
9.10.Market Attractiveness Analysis
9.10.1. By Country
9.10.2. By Treatment Type
9.10.3. By Route of Administration
9.10.4. By End User
9.11.Drivers and Restraints: Impact Analysis
9.12.Key Market Participants – Intensity Mapping
10. Asia Pacific Excluding Japan (APEJ) Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028
10.1.Introduction
10.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017
10.2.1. China
10.2.2. India
10.2.3. Australia and New Zealand
10.2.4. ASEAN
10.2.5. Rest of APEJ
10.3.Market Size (US$ Mn) Forecast By Country, 2018-2028
10.4.Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013-2017
10.4.1. Non-steroidal anti-inflammatory medications (NSAIDs)
10.4.2. Opioids
10.4.3. Stem Cell Therapy
10.4.3.1. Allogeneic Stem Cell
10.4.3.2. Autologous Stem Cell
10.5.Market Size (US$ Mn) Forecast By Treatment Type, 2018-2028
10.6.Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017
10.6.1. Oral
10.6.2. Injectable
10.7.Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028
10.8.Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017
10.8.1. Veterinary Hospitals & Clinics
10.8.2. Retail Pharmacies
10.8.3. Drug Stores
10.8.4. E-commerce
10.9.Market Size (US$ Mn) Forecast By End User, 2018-2028
10.10. Market Attractiveness Analysis
10.10.1. By Country
10.10.2. By Treatment Type
10.10.3. By Route of Administration
10.10.4. By End User
10.11. Drivers and Restraints: Impact Analysis
10.12. Key Market Participants – Intensity Mapping
11. Japan Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028
11.1.Introduction
11.2.Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013-2017
11.2.1. Non-steroidal anti-inflammatory medications (NSAIDs)
11.2.2. Opioids
11.2.3. Stem Cell Therapy
11.2.3.1. Allogeneic Stem Cell
11.2.3.2. Autologous Stem Cell
11.3.Market Size (US$ Mn) Forecast By Treatment Type, 2018-2028
11.4.Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017
11.4.1. Oral
11.4.2. Injectable
11.5.Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028
11.6.Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017
11.6.1. Veterinary Hospitals & Clinics
11.6.2. Retail Pharmacies
11.6.3. Drug Stores
11.6.4. E-commerce
11.7.Market Size (US$ Mn) Forecast By End User, 2018-2028
11.8.Market Attractiveness Analysis
11.8.1. By Treatment Type
11.8.2. By Route of Administration
11.8.3. By End User
11.9.Drivers and Restraints: Impact Analysis
11.10. Key Market Participants – Intensity Mapping
12. Middle East and Africa Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028
12.1.Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017
12.2.1. GCC Countries
12.2.2. South Africa
12.2.3. Rest of Middle East and Africa
12.3.Market Size (US$ Mn) Forecast By Country, 2018-2028
12.4.Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013-2017
12.4.1. Non-steroidal anti-inflammatory medications (NSAIDs)
12.4.2. Opioids
12.4.3. Stem Cell Therapy
12.4.3.1. Allogeneic Stem Cell
12.4.3.2. Autologous Stem Cell
12.5.Market Size (US$ Mn) Forecast By Treatment Type, 2018-2028
12.6.Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017
12.6.1. Oral
12.6.2. Injectable
12.7.Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028
12.8.Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017
12.8.1. Veterinary Hospitals & Clinics
12.8.2. Retail Pharmacies
12.8.3. Drug Stores
12.8.4. E-commerce
12.9.Market Size (US$ Mn) Forecast By End User, 2018-2028
12.10. Market Attractiveness Analysis
12.10.1. By Country
12.10.2. By Treatment Type
12.10.3. By Route of Administration
12.10.4. By End User
12.11. Drivers and Restraints: Impact Analysis
12.12. Key Market Participants – Intensity Mapping
13. Forecast Factors: Relevance and Impact
14. Forecast Assumptions
15. Competition Analysis
15.1.Competition Dashboard
15.2.Company Deep Dive
15.2.1. Elanco (Eli Lily and Company)
15.2.1.1. Overview
15.2.1.2. Product and Application Portfolio
15.2.1.3. Production Footprint
15.2.1.4. Sales Footprint
15.2.1.5. Channel Footprint
15.2.1.6. Strategy
15.2.1.6.1. Marketing Strategy
15.2.1.6.2. Product Strategy
15.2.1.6.3. Channel Strategy
15.2.2. Ceva Santé Animale
15.2.2.1. Overview
15.2.2.2. Product and Application Portfolio
15.2.2.3. Production Footprint
15.2.2.4. Sales Footprint
15.2.2.5. Channel Footprint
15.2.2.6. Strategy
15.2.2.6.1. Marketing Strategy
15.2.2.6.2. Product Strategy
15.2.2.6.3. Channel Strategy
15.2.3. Vetoquinol S.A.
15.2.3.1. Overview
15.2.3.2. Product and Application Portfolio
15.2.3.3. Production Footprint
15.2.3.4. Sales Footprint
15.2.3.5. Channel Footprint
15.2.3.6. Strategy
15.2.3.6.1. Marketing Strategy
15.2.3.6.2. Product Strategy
15.2.3.6.3. Channel Strategy
15.2.4. Norbrook Laboratories Limited
15.2.4.1. Overview
15.2.4.2. Product and Application Portfolio
15.2.4.3. Production Footprint
15.2.4.4. Sales Footprint
15.2.4.5. Channel Footprint
15.2.4.6. Strategy
15.2.4.6.1. Marketing Strategy
15.2.4.6.2. Product Strategy
15.2.4.6.3. Channel Strategy
15.2.5. Aratana Therapeutics Inc.
15.2.5.1. Overview
15.2.5.2. Product and Application Portfolio
15.2.5.3. Production Footprint
15.2.5.4. Sales Footprint
15.2.5.5. Channel Footprint
15.2.5.6. Strategy
15.2.5.6.1.1. Marketing Strategy
15.2.5.6.1.2. Product Strategy
15.2.5.6.1.3. Channel Strategy
15.2.6. Boehringer Ingelheim
15.2.6.1. Overview
15.2.6.2. Product and Application Portfolio
15.2.6.3. Production Footprint
15.2.6.4. Sales Footprint
15.2.6.5. Channel Footprint
15.2.6.6. Strategy
15.2.6.6.1. Marketing Strategy
15.2.6.6.2. Product Strategy
15.2.6.6.3. Channel Strategy
15.2.7. Zoetis Inc.
15.2.7.1. Overview
15.2.7.2. Product and Application Portfolio
15.2.7.3. Production Footprint
15.2.7.4. Sales Footprint
15.2.7.5. Channel Footprint
15.2.7.6. Strategy
15.2.7.6.1. Marketing Strategy
15.2.7.6.2. Product Strategy
15.2.7.6.3. Channel Strategy
15.2.8. Bayer AG
15.2.8.1. Overview
15.2.8.2. Product and Application Portfolio
15.2.8.3. Production Footprint
15.2.8.4. Sales Footprint
15.2.8.5. Channel Footprint
15.2.8.6. Strategy
15.2.8.6.1. Marketing Strategy
15.2.8.6.2. Product Strategy
15.2.8.6.3. Channel Strategy
15.2.9. VetStem Biopharma
15.2.9.1. Overview
15.2.9.2. Product and Application Portfolio
15.2.9.3. Production Footprint
15.2.9.4. Sales Footprint
15.2.9.5. Channel Footprint
15.2.9.6. Strategy
15.2.9.6.1. Marketing Strategy
15.2.9.6.2. Product Strategy
15.2.9.6.3. Channel Strategy
15.2.10. Dechra Pharmaceuticals PLC
15.2.10.1. Overview
15.2.10.2. Product and Application Portfolio
15.2.10.3. Production Footprint
15.2.10.4. Sales Footprint
15.2.10.5. Channel Footprint
15.2.10.6. Strategy
15.2.10.6.1. Marketing Strategy
15.2.10.6.2. Product Strategy
15.2.10.6.3. Channel Strategy
16. Global Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028 By Region
16.1. Introduction / Key Findings
16.2. Historical Market Size (US$ Mn) Analysis By Region
16.2.1. North America
16.2.2. Latin America
16.2.3. Europe
16.2.4. Asia Pacific Excluding Japan
16.2.5. Japan
16.2.6. Middle East and Afica
16.3. Market Size (US$ Mn) Forecast By Region, 2018-2028
16.4. Market Attractiveness Analysis By Region
17. Global Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Treatment Type
17.1. Introduction/Key Finding
17.2.Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013-2017
17.2.1. Non-steroidal anti-inflammatory medications (NSAIDs)
17.2.2. Opioids
17.2.3. Stem Cell Therapy
17.2.3.1. Allogeneic Stem Cell
17.2.3.2. Autologous Stem Cell
17.3. Market Size (US$ Mn) Forecast By Treatment Type, 2018-2028
17.4. Market Attractiveness Analysis By Treatment Type
18. Global Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Route of Administration
18.1. Introduction/Key Finding
18.2.Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017
18.2.1. Oral
18.2.2. Injectable
18.3. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028
18.4. Market Attractiveness Analysis By Route of Administration
19. Global Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By End User
19.1.Introduction/Key Finding
19.2.Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017
19.2.1. Veterinary Hospitals & Clinics
19.2.2. Retail Pharmacies
19.2.3. Drug Stores
19.2.4. E-commerce
19.3.Market Size (US$ Mn) Forecast By End User, 2018-2028
19.4.Market Attractiveness Analysis By End User
20. Global Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028
20.1.Market Value Share Analysis By All Segment
20.2.Y-o-Y Growth Analysis By All Segment
20.3.Absolute $ Opportunity
21. Assumptions and Acronyms Used
22. Research Methodology
【レポートのキーワード】
犬関節炎治療薬
【免責事項】
http://www.globalresearch.jp/disclaimer